Clinical Practice Recommendations For The Management And Prevention Of Cisplatin-Induced Hearing Loss Using Pharmacogenetic Markers

Lee, Jong W; Pussegoda, Kusala; Rassekh, Rod S; Monzon, Jose G; Liu, Geoffrey; Hwang, Soomi; Bhavsar, Amit P; Pritchard, Sheila; Ross, Colin J; Carleton, Bruce C; Amstutz, Ursula (2016). Clinical Practice Recommendations For The Management And Prevention Of Cisplatin-Induced Hearing Loss Using Pharmacogenetic Markers. Therapeutic drug monitoring, 38(4), p. 1. Lippincott Williams & Wilkins 10.1097/FTD.0000000000000298

Preview

Text 00007691-900000000-99186.pdf - Accepted Version Available under License Publisher holds Copyright. Download (881kB) | Preview

Currently no pharmacogenomics-based criteria exist to guide clinicians in identifying individuals who are at risk of hearing loss from cisplatin-based chemotherapy. This review summarizes findings from pharmacogenomic studies that report genetic polymorphisms associated with cisplatin-induced hearing loss and aims to (1) provide up-to-date information on new developments in the field; (2) provide recommendations for the use of pharmacogenetic testing in the prevention, assessment and management of cisplatin-induced hearing loss in children and adults; and (3) identify knowledge gaps to direct and prioritize future research. These practice recommendations for pharmacogenetic testing in the context of cisplatin-induced hearing loss reflect a review and evaluation of recent literature and are designed to assist clinicians in providing optimal clinical care for patients receiving cisplatin based chemotherapy.

Interest & Impact

Downloads

801 since deposited on 24 May 2016
133 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item